Venture • Life Science

EQT Life Sciences Invests In Cardior

On May 11, 2017, growth capital firm EQT Life Sciences invested in life science company Cardior

Investment Context
  • This is EQT Life Sciences’ 8th transaction in the Life Science sector.
  • This is EQT Life Sciences’ 3rd transaction in Germany.
Investment Fate
  • Cardior was sold to a publicly-traded strategic buyer in 2024 for 1.0B USD.

Explore All 557 Venture Life Science Deals - Search the Database Free


Investment Summary

Date May 11, 2017
Target Cardior
Sector Life Science
Investor(s) EQT Life Sciences
Deal Type Venture

Target Company

Cardior

Hannover, Germany
Cardior is a clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair, and reverse diseases of the heart. The company's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. Cardior was founded in 2016 and is based in Hannover, Germany.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

Investor

EQT Life Sciences


Category Growth Capital Firm
Founded 1987
PE ASSETS 3.5B EUR
Size Large
Type Sector Focused
DESCRIPTION

EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid?stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.


Deal Context for Investor #
Overall 15 of 47
Sector: Life Science 8 of 30
Type: Venture 12 of 39
Country: Germany 3 of 4
Year: 2017 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-02 Imcheck Therapeutics

Marseilles, France

ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-07-19 Simplify

Sunnyvale, California, United States

Simplify is a medical device company focused on cervical spinal disc arthroplasty, using innovative, MRI-compatible materials designed to optimize diagnostic imaging and decrease the need for ionizing radiation. Simplify was founded in 2013 and is based in Sunnyvale, California.

Buy -

Explore Related M&A Activity